{
  "attach_pages": "5",
  "attach_size": "422",
  "attach_type": "0",
  "attach_url": "https://pdf.dfcfw.com/pdf/H3_AP202004011377332641_1.pdf?1585733432000.pdf",
  "company_code": "80000038",
  "eitime": "2020-04-01 09:30:32",
  "extend": {},
  "info_code": "AP202004011377332641",
  "language": "0",
  "notice_date": "2020-04-01 00:00:00",
  "notice_title": "复星医药2019年业绩点评：内生业务增长强劲，创新增量有望带来业绩拐点",
  "page_size": 1,
  "page_size_ch": 0,
  "page_size_cht": 0,
  "page_size_en": 0,
  "rating": "BB",
  "researcher": "孙建,郭双喜",
  "security": [
    {
      "market_uni": "1",
      "publish_relation": [
        {
          "originalCode": "465",
          "publishName": "化学制药"
        }
      ],
      "short_name": "复星医药",
      "short_name_ch": "复星医药",
      "short_name_cht": "復星醫藥",
      "short_name_en": "FOSUN PHARMA",
      "stock": "600196"
    }
  ],
  "short_name": "复星医药",
  "source_sample_name": "民生证券",
  "star": "3"
}